Literature DB >> 23224516

A proposal for an additional clinical trial outcome measure assessing preventive effect as delay of events.

Per Lytsy1, Lars Berglund, Johan Sundström.   

Abstract

Many effect measures used in clinical trials are problematic because they are differentially understood by patients and physicians. The emergence of novel methods such as accelerated failure-time models and quantile regression has shifted the focus of effect measurement from probability measures to time-to-event measures. Such modeling techniques are rapidly evolving, but matching non-parametric descriptive measures are lacking. We propose such a measure, the delay of events, demonstrating treatment effect as a gain in event-free time. We believe this measure to be of value for shared clinical decision-making. The rationale behind the measure is given, and it is conceptually explained using the Kaplan-Meier estimate and the quantile regression framework. A formula for calculation of the delay of events is given. Hypothetical and empirical examples are used to demonstrate the measure. The measure is discussed in relation to other measures highlighting the time effects of preventive treatments. There is a need to further investigate the properties of the measure as well as its role in clinical decision-making.

Entities:  

Mesh:

Year:  2012        PMID: 23224516      PMCID: PMC3539066          DOI: 10.1007/s10654-012-9752-0

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  22 in total

1.  Danish GPs' perception of disease risk and benefit of prevention.

Authors:  Jørgen Nexøe; Dorte Gyrd-Hansen; Jakob Kragstrup; Ivar Sønbø Kristiansen; Jesper Bo Nielsen
Journal:  Fam Pract       Date:  2002-02       Impact factor: 2.267

2.  Absolutely relative: how research results are summarized can affect treatment decisions.

Authors:  L Forrow; W C Taylor; R M Arnold
Journal:  Am J Med       Date:  1992-02       Impact factor: 4.965

3.  The effect of alternative summary statistics for communicating risk reduction on decisions about taking statins: a randomized trial.

Authors:  Cheryl L L Carling; Doris Tove Kristoffersen; Victor M Montori; Jeph Herrin; Holger J Schünemann; Shaun Treweek; Elie A Akl; Andrew D Oxman
Journal:  PLoS Med       Date:  2009-08-25       Impact factor: 11.069

4.  The framing effect of relative and absolute risk.

Authors:  D J Malenka; J A Baron; S Johansen; J W Wahrenberger; J M Ross
Journal:  J Gen Intern Med       Date:  1993-10       Impact factor: 5.128

5.  Gains in life expectancy from medical interventions--standardizing data on outcomes.

Authors:  J C Wright; M C Weinstein
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

6.  Number needed to treat: easily understood and intuitively meaningful? Theoretical considerations and a randomized trial.

Authors:  Ivar Sønbø Kristiansen; Dorte Gyrd-Hansen; Jørgen Nexøe; Jesper Bo Nielsen
Journal:  J Clin Epidemiol       Date:  2002-09       Impact factor: 6.437

7.  Primary prevention drug therapy: can it meet patients' requirements for reduced risk?

Authors:  Hilary A Llewellyn-Thomas; J Michael Paterson; Judy A Carter; Antoni Basinsk; Martin G Myers; Gordon D Hardacre; Earl V Dunn; Ralph B D'Agostino; Philip A Wolf; C David Naylor
Journal:  Med Decis Making       Date:  2002 Jul-Aug       Impact factor: 2.583

8.  Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment?

Authors:  J E Hux; C D Naylor
Journal:  Med Decis Making       Date:  1995 Apr-Jun       Impact factor: 2.583

9.  Evidence that obesity risk factor potencies are weight dependent, a phenomenon that may explain accelerated weight gain in western societies.

Authors:  Paul T Williams
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

10.  Can postponement of an adverse outcome be used to present risk reductions to a lay audience? A population survey.

Authors:  Rasmus Dahl; Dorte Gyrd-Hansen; Ivar Sønbø Kristiansen; Jørgen Nexøe; Jesper Bo Nielsen
Journal:  BMC Med Inform Decis Mak       Date:  2007-03-29       Impact factor: 2.796

View more
  6 in total

1.  The Rotterdam Study: 2014 objectives and design update.

Authors:  Albert Hofman; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2013-11-21       Impact factor: 8.082

2.  Postponement of Death by Statin Use: a Systematic Review and Meta-analysis of Randomized Clinical Trials.

Authors:  Morten Rix Hansen; Asbjørn Hróbjartsson; Anton Pottegård; Per Damkier; Kasper Søltoft Larsen; Kenneth Grønkjær Madsen; René dePont Christensen; Malene Elisa Lopez Kristensen; Palle Mark Christensen; Jesper Hallas
Journal:  J Gen Intern Med       Date:  2019-05-09       Impact factor: 5.128

3.  A novel method for interpreting survival analysis data: description and test on three major clinical trials on cardiovascular prevention.

Authors:  Alessandro Mengozzi; Domenico Tricò; Andrea Natali
Journal:  Trials       Date:  2020-06-26       Impact factor: 2.279

4.  Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry.

Authors:  Giulio Francesco Romiti; Marco Proietti; Giuseppe Boriani; Gregory Y H Lip; Marco Vitolo; Niccolò Bonini; Ameenathul Mazaya Fawzy; Wern Yew Ding; Laurent Fauchier; Francisco Marin; Michael Nabauer; Gheorghe Andrei Dan; Tatjana S Potpara
Journal:  BMC Med       Date:  2022-09-02       Impact factor: 11.150

5.  Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial.

Authors:  Andrea Bellavia; Lars Wallentin; Nicola Orsini; Stefan K James; Christopher P Cannon; Anders Himmelmann; Johan Sundström; Henrik Renlund; Per Lytsy
Journal:  Open Heart       Date:  2017-06-01

6.  Length of time periods in treatment effect descriptions and willingness to initiate preventive therapy: a randomised survey experiment.

Authors:  Erik Berglund; Ragnar Westerling; Johan Sundström; Per Lytsy
Journal:  BMC Med Inform Decis Mak       Date:  2018-11-20       Impact factor: 2.796

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.